Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.

British Journal of Haematology
Ascensión López-Díaz de CerioCarlos Panizo

Abstract

Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after this treatment. We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy. This open, prospective, phase II, single-arm study assessed safety and efficacy of ex vivo expanded LAK cells in 20 FL-remission patients following rituximab maintenance. Mononuclear cells were obtained in odd rituximab cycles and stimulated with interleukin 2 (IL-2) for 8 weeks, after which >5 × 108 LAK cells were injected. Patients were followed-up for 5 years. At the end of maintenance, peripheral blood cells phenotype had not changed markedly. Natural killer, LAK and ADCC activities of mononuclear cells increased significantly after recombinant human IL-2 (rhIL-2) stimulation in all cycles. Rituximab significantly enhanced cytotoxic activity. No patients discontinued treatment. There were no treatment-related serious adverse events. Three patients had progressed by the end of follow-up. After a median (interq...Continue Reading

References

Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jesús G BerdejaIan W Flinn
Feb 28, 2009·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Neil W ScottUNKNOWN EORTC Quality of Life Group and the Quality of Life Cross-Cultural Meta-Analysis Group
Dec 12, 2012·Cancer Treatment Reviews·Marcin OkrojAnna M Blom
Oct 2, 2014·Current Opinion in Chemical Biology·Rodney A RosaliaOnur Boyman
Feb 20, 2015·Hematology·Catherine M Bollard, A John Barrett
Jun 2, 2015·Frontiers in Immunology·Gianfranco PittariSergio Rutella
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Mar 19, 2016·Blood·Brad S Kahl, David T Yang
Sep 26, 2016·Blood Reviews·Geoffrey S KannanDean A Lee
Apr 6, 2017·Hematological Oncology·Randy D GascoyneEmanuele Zucca
Apr 25, 2017·Cancer Management and Research·Barbara Ma, Chaitra Ujjani
Jul 22, 2017·Frontiers in Immunology·Xingchun GaoWeilin Jin
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Feb 10, 2018·Nature Reviews. Cancer·Sarah HuetGilles Salles

❮ Previous
Next ❯

Citations

Mar 26, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasheed M Hossain, Patrick J Stiff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.